STK33 and neoplasm: On the other hand, it is demonstrated that inhibition of HSP90 (by shRNA or small molecules) led to a decrease in protein content of STK33 and reduction of viability in vitro and tumor growth rate in vivo for KRAS mutant CRC cell lines (Azoitei et al., 2012).